The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT

European Journal of Heart Failure

Volumn 16, Issue 4, 2014, Pages 426-434

  Voors, Adriaan A ^a   Van Veldhuisen, Dirk J ^a   Robertson, Michele ^b   Ford, Ian ^b   Borer, Jeffrey S ^c   Böhm, Michael ^d   Komajda, Michel ^e   Swedberg, Karl ^f   Tavazzi, Luigi ^g  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d SAARLAND UNIVERSITY   (Germany)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Heart failure; Heart rate; Ivabradine; Renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE; MINERALOCORTICOID ANTAGONIST; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CYCLIC NUCLEOTIDE GATED CHANNEL;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLURRED VISION; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY DISEASE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ADULT; AGED; BENZAZEPINES; CARDIOVASCULAR AGENTS; CREATININE; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 84924051212     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.59     Document Type: Article

References (25)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
2. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA,. The role of the kidney in heart failure. Eur Heart J 2012; 33: 2135-2142.
3. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL,. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2013;PMID:24164864 [Epub ahead of print].
4. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, Van Veldhuisen DJ, Hillege HL,. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13: 599-608.
5. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM,. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996.
6. DiFrancesco D,. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006; 53: 399-406.
7. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L,. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010; 12: 75-81.
8. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
9. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL,. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872-878.
10. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC,. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008; 154: 749-757.
11. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL,. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-1580.
12. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ,. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009; 11: 847-854.
13. Böhm M, Thoenes M, Neuberger HR, Gräber S, Reil JC, Bramlage P, Volpe M,. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 2009; 30: 1364-1371.
14. Böhm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M,. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26: 18-25.
15. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R,; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821.
16. Borer JS, Böhm M, Ford I, Komajda M, Tavazzi L, Sendon JL, Alings M, Lopez-de-Sa E, Swedberg K,. on behalf of the SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33: 2813-2820.
17. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, Dargie HJ,. CIBIS-2 Investigators and Committees. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12: 974-982.
18. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U,. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117: 2377-2387.
19. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN,. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009; 120: 1577-1584.
20. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ,. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678.
21. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, Clark AL, Cleland JG,. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27: 569-581.
22. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A,. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006; 17: 244-253.
23. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA,. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 10: 2886-2891.
24. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM,; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
25. Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL,. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 2012; 98: 319-324.